Takeda Completes Sale of Select OTC and Non-Core Assets to STADA
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK)
Company Research
Source: Business Wire
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to STADA Arzneimittel AG (“STADA”) for a total value of $660 million USD. The portfolio includes approximately 20 over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth & Emerging Markets Business Unit. This divestment agreement was first announced in November 2019.The divested portfolio includes OTC Vitamins and Food Supplements, plus select products within the Cardiovascular, Diabetes, General Medicine, and Respiratory therapeutic areas, which are outside of the business areas Takeda has chosen as core to its global long-term growth. As previously announced, Takeda and STADA have also entered into manufacturing and supply agreements
Show less
Read more
Impact Snapshot
Event Time:
TAK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TAK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TAK alerts
High impacting Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) news events
Weekly update
A roundup of the hottest topics
TAK
News
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform [Yahoo! Finance]Yahoo! Finance
- Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy PlatformBusiness Wire
- Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair [Yahoo! Finance]Yahoo! Finance
- New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD [Yahoo! Finance]Yahoo! Finance
- Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook [Yahoo! Finance]Yahoo! Finance
TAK
Sec Filings
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- 10/31/24 - Form 6-K
- TAK's page on the SEC website